m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03717)
Name
ISIS 17148
Status
Investigative
TTD Drug ID
D0O3DZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Signal transducer and activator of transcription 3 (STAT3)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). [2], [3]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). [2], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). [2], [4]
References
Ref 1 FTO inhibits UPR(mt)-induced apoptosis by activating JAK2/STAT3 pathway and reducing m6A level in adipocytes. Apoptosis. 2021 Aug;26(7-8):474-487. doi: 10.1007/s10495-021-01683-z. Epub 2021 Jul 1.
Ref 2 US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
Ref 3 N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1. Front Cell Dev Biol. 2021 Dec 7;9:731810. doi: 10.3389/fcell.2021.731810. eCollection 2021.
Ref 4 ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner. EBioMedicine. 2022 Jun;80:104019. doi: 10.1016/j.ebiom.2022.104019. Epub 2022 Apr 28.